On September 10, 2020 Incurix reported that it made an agreement with National OncoVenture (NOV) of the National Cancer Center (NCC) for cooperation in research and development of c-myc inhibitor ‘ICX-101’ (Press release, Incurix, SEP 10, 2020, View Source;idx=69&page=1&code=news [SID1234643570]). ICX-101, the program on which the joint research agreement was made, is a candidate substance Incurix in-licensed from the National Cancer Center (NCC) and the Korea Research Institute of Chemical Technology (KRICT) in April. The c-myc protein, the target of ICX-101, is cell proliferation- and death-mediated transcription factor. The c-myc protein is key to the occurrence, growth and metastasis of cancer, and is over-expressed in various cancers, such as hematologic malignancy, lung cancer, breast cancer and central nervous system tumor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Although the c-myc is an important target in anti-cancer drug development, no drug of c-myc target has been developed yet because of technological problems," Incurix CEO Kyung-Chae Jeong said. He added, "We will develop ICX-101 in partnership with National OncoVenture."